Career Enhancement Program

$8,612P50FY2025CANIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications & trials

Paper 39730160 Paper 39723472 Paper 39572533 Paper 39535237 Paper 39377927 Paper 39149696 Paper 39091877 Paper 39011735 Paper 38982561 Paper 38958972 Paper 38856710 Paper 38837899 Paper 38808755 Paper 38719809 Paper 38719607 Paper 38616896 Paper 38501824 Paper 38445960 Paper 38441553 Paper 38353122 Paper 38238098 Paper 38224404 Paper 37841696 Paper 37830597 Paper 37774317 Paper 37655659 Paper 37591790 Paper 37546917 Paper 37541280 Paper 37540556 Paper 37402043 Paper 37294422 Paper 37279645 Paper 37238150 Paper 37236196 Paper 37152809 Paper 37140454 Paper 37128507 Paper 37069149 Paper 37053159 Paper 37034584 Paper 36930646 Paper 36917358 Paper 36847506 Paper 36831380 Paper 36823302 Paper 36759899 Paper 36744986 Paper 36712018 Paper 36711497 Paper 36702828 Paper 36691871 Paper 36685009 Paper 36649303 Paper 36640127 Paper 36635088 Paper 36617262 Paper 36509998 Paper 36472553 Paper 36445342 Paper 36416495 Paper 36394838 Paper 36301349 Paper 36261421 Paper 36261010 Paper 36239925 Paper 36213002 Paper 36192632 Paper 36183571 Paper 36178522 Paper 36125064 Paper 36113740 Paper 36053452 Paper 35985343 Paper 35917833 Paper 35853075 Paper 35740680 Paper 35738905 Paper 35736864 Paper 35704275 Paper 35626127 Paper 35583041 Paper 35521707 Paper 35419607 Paper 35386566 Paper 35241842 Paper 35201903 Paper 35178111 Paper 35115362 Paper 34990726 Paper 34911188 Paper 34887515 Paper 34865129 Paper 34836966 Paper 34608074 Paper 34570454 Paper 34494550 Paper 34446457 Paper 34433969 Paper 34375132

Abstract

The studies proposed herein are designed to test the feasibility, safety, and preliminary efficacy of a novel IL-13Ra2/IL-12/DR-18 CAR-T cell therapy for glioblastoma, as well as investigate response biomarkers and mechanisms of immune evasion following the injection of these CAR-T cells intratumorally and intraventricularly. We will test our hypothesis that clinically relevant CAR-T cell therapy for glioblastoma (GBM) must have two components: 1) tumor specific glioblastoma cell targeting; and 2) blockade of the immunosuppressive tumor microenvironment (TME). We believe that our novel IL-13Ra2/IL-12/DR-18 CAR-T cell therapy that simultaneously targets both glioblastoma cells and the immunosuppressive TME may lead to improved outcomes for the treatment of glioblastoma.

View original record on NIH RePORTER →